Rocket Lab USA, Inc. (RKLB) Stock Forecast
Data as of Sep 16, 2026Industrials · Current price $63.88 (+0.57%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Andres Sheppard | Cantor Fitzgerald | $85.00 | +33.1% |
| Jan 20, 2026 | Anthony Valentini | Goldman Sachs | $69.00 | +8.0% |
| Jan 16, 2026 | Kristine Liwag | Morgan Stanley | $105.00 | +64.4% |
| Dec 23, 2025 | Ryan Koontz | Needham | $90.00 | +40.9% |
| Nov 12, 2025 | Ryan Koontz | Needham | $63.00 | -1.4% |
| Nov 11, 2025 | Suji Desilva | Roth Capital | $75.00 | +17.4% |
| Nov 11, 2025 | Erik Rasmussen | Stifel Nicolaus | $75.00 | +17.4% |
| Oct 15, 2025 | Peter Arment | Robert W. Baird | $83.00 | +29.9% |
| Jul 14, 2025 | Andres Sheppard | Cantor Fitzgerald | $35.00 | -45.2% |
| Jan 8, 2025 | Erik Rasmussen | Stifel Nicolaus | $31.00 | -51.5% |
| Oct 23, 2024 | Mike Leschock | KeyBanc | $12.00 | -81.2% |
| Sep 27, 2024 | Mike Leschock | KeyBanc | $11.00 | -82.8% |
| Jul 15, 2024 | Kristine Liwag | Morgan Stanley | $6.00 | -90.6% |
| Jun 11, 2024 | Noah Poponak | Goldman Sachs | $4.50 | -93.0% |
| May 7, 2024 | Erik Rasmussen | Stifel Nicolaus | $9.00 | -85.9% |
| Feb 12, 2024 | Jason Gursky | Citigroup | $6.00 | -90.6% |
| Jan 17, 2024 | Michael Leshock | KeyBanc | $8.00 | -87.5% |
| Sep 27, 2023 | Erik Rasmussen | Stifel Nicolaus | $10.00 | -84.3% |
| Aug 31, 2022 | Sam Boughedda | Cowen & Co. | $8.00 | -87.5% |
| Jun 21, 2022 | Matthew Akers | Wells Fargo | $5.00 | -92.2% |
Top Analysts Covering RKLB
RKLB vs Sector & Market
| Metric | RKLB | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.05 | 2.40 | 2.42 |
| Analyst Count | 19 | 8 | 18 |
| Target Upside | +72.0% | +112.0% | +19.5% |
| P/E Ratio | -227.00 | 35.04 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $827M | $860M | $937M | 11 |
| 2027-03-31 | $237M | $253M | $295M | 4 |
| 2027-06-30 | $281M | $300M | $350M | 6 |
| 2027-09-30 | $274M | $293M | $342M | 4 |
| 2027-12-31 | $308M | $329M | $384M | 7 |
| 2028-03-31 | $328M | $351M | $409M | 3 |
| 2028-06-30 | $373M | $399M | $465M | 5 |
| 2028-09-30 | $380M | $406M | $473M | 3 |
| 2028-12-31 | $424M | $453M | $528M | 6 |
| 2029-12-31 | $1.69B | $1.98B | $2.36B | 7 |
| 2030-12-31 | $2.13B | $2.49B | $2.96B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.27 | $-0.18 | $-0.09 | 9 |
| 2027-03-31 | $-0.02 | $-0.02 | $-0.01 | 1 |
| 2027-06-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2027-09-30 | $0.00 | $0.00 | $0.01 | 1 |
| 2027-12-31 | $0.01 | $0.01 | $0.02 | 1 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2029-12-31 | $0.43 | $0.54 | $0.67 | 2 |
| 2030-12-31 | $0.69 | $0.84 | $1.06 | 2 |
Frequently Asked Questions
What is the analyst consensus for RKLB?
The consensus among 19 analysts covering Rocket Lab USA, Inc. (RKLB) is Buy with an average price target of $109.20.
What is the highest price target for RKLB?
The highest price target for RKLB is $105.00, set by Kristine Liwag at Morgan Stanley on 2026-01-16.
What is the lowest price target for RKLB?
The lowest price target for RKLB is $4.50, set by Noah Poponak at Goldman Sachs on 2024-06-11.
How many analysts cover RKLB?
19 analysts have issued ratings for Rocket Lab USA, Inc. in the past 12 months.
Is RKLB a buy or sell right now?
Based on 19 analyst ratings, RKLB has a consensus rating of Buy (2.05/5) with a +72.0% upside to the consensus target of $109.20.
What are the earnings estimates for RKLB?
Analysts estimate RKLB will report EPS of $-0.18 for the period ending 2026-12-31, with revenue estimated at $860M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.